Open AccessStatins: in the beginning
Author(s) -
Kristopher Lyons,
Mark Harbinson
Publication year - 2009
Publication title -
journal of the royal college of physicians of edinburgh/the journal of the royal college of physicians of edinburgh
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.275
H-Index - 26
eISSN - 2042-8189
pISSN - 1478-2715
DOI - 10.4997/jrcpe.2009.425
Subject(s) - hmg coa reductase , hydroxymethylglutaryl coa reductase inhibitors , reductase , drug , class (philosophy) , drug class , medicine , coenzyme a , statin , pharmacology , computer science , biology , enzyme , biochemistry , artificial intelligence
Since the first human trial of a hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitor in 1978, the growth in importance of this drug class, both financially and medically, has been staggering. The aim of this paper is to summarise how this drug class was developed, highlighting the role ofAkira Endo.